Effects of CRRT on renal function and toxin clearance in patients with sepsis: a case–control study

Jinzhong Wang, Zhongyong Wu, Quan Wen and Xiaozhi Wang

Abstract

Objective: To explore the effects of continuous renal replacement therapy (CRRT) on renal function and toxin clearance in patients with sepsis and concurrent acute kidney injury (AKI).

Method: A retrospective analysis was performed using the medical records of 115 patients with sepsis and AKI. Among them, 60 patients received routine treatment (group A) and 55 patients received CRRT plus routine treatment (group B).

Result: After treatment, the clearance rates of serum creatinine, lactic acid, and urea nitrogen were significantly lower in group A than in group B. The decrease in high-sensitivity C-reactive protein and tumor necrosis factor-α levels after treatment was significantly higher in group B than in group A. For the Acute Physiology Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores from the two groups, the scores were significantly lower in group B than in group A. The mortality rate within 28 days was significantly higher in group A than in group B.

Conclusion: CRRT can effectively improve the condition of patients with sepsis and AKI, promote elimination of toxins (serum creatinine, lactic acid, and urea nitrogen) from the body, and reduce the mortality rate.

Keywords

Acute kidney injury, survival, mortality rate, toxin, Acute Physiology Chronic Health Evaluation II, Sequential Organ Failure Assessment, C-reactive protein, tumor necrosis factor alpha

Date received: 11 March 2020; accepted: 10 August 2021
Introduction

Sepsis refers to the systemic inflammatory response syndrome that is caused by infection, and it is often accompanied by acute kidney injury (AKI). There are over 18 million new patients who are diagnosed with sepsis every year, and the incidence is increasing yearly. Patients with sepsis in China have a 30% to 60% chance of having accompanying acute renal injury, and the mortality rate is as high as 30% to 80%. Patients who reached AKI stage 3 and did not need RRT had the lowest mortality. However, due to the high hospitalization cost that is associated with sepsis and concurrent AKI, many families cannot afford treatment. Thus, the disease is not alleviated through effective management, and patients eventually stop their treatment, resulting in more deaths. The associated high morbidity and mortality rates are critical problems for the medical team.

Currently, the conventional clinical treatment of sepsis is intravenous infusion and antibiotics, which does not have the expected clinical effect. Continuous renal replacement therapy (CRRT) is the standard of care for the management of critically ill patients with acute renal failure. CRRT is indicated in patients who meet the criteria for hemodialysis therapy but who cannot tolerate conventional intermittent hemodialysis (IHD) due to hemodynamic instability. Its main purpose is to rebuild the body’s immune function using inflammatory mediators to control the patient’s systemic response and achieve a therapeutic goal.

This study aimed to determine the effects of CRRT on renal function and toxin clearance rate (i.e. serum creatinine, lactic acid, and urea nitrogen) in patients with sepsis and concurrent AKI and the effect on risk factors for a poor patient prognosis to provide a reference for clinicians.

Materials and methods

Patients

This was a retrospective analysis of 115 patients with sepsis and AKI. Patients were categorized into the routine treatment (group A) and CRRT + routine treatment groups (group B) on the basis of the treatment that they received. There were 60 patients in group A and 55 patients in group B. All patients met the diagnostic criteria for sepsis in accordance with the new definitions for sepsis and septic shock (Sepsis-3) from the 1991 American Association of Chest Physicians/Clinical Medicine Association Consensus Conference and the 2012 KDIGO Guidelines.

Inclusion and exclusion criteria

The inclusion criteria were as follows: availability of complete clinical data; did not receive hormonal therapy or immune preparations within 3 months before hospitalization; hospitalized for <72 hours; and had not undergone kidney transplantation. The patients and their family members agreed to the patients’ participation in the study and provided written informed consent. This study was approved by the Medical Ethics Committee of the Second Affiliated Hospital of Hainan Medical University. The reporting of this study conforms to STROBE guidelines.

The exclusion criteria were as follows: presence of malignant tumors; confirmed or suspected AKI caused by pre-renal, post-renal, or acute glomerulonephritis or other chronic diseases; or patients with an immunodeficiency disease.

Treatment programs

Patients in group A were treated with the routine treatment program as described below. Briefly, patients underwent fluid
resuscitation, and functional support was provided. The patient’s internal circulation improved, and severe acute respiratory distress syndrome was treated. On the basis of the bacterial culture and pathogen detection test results, antibiotics were administered. The patients’ internal electrolyte balance was maintained, and protection and support for the patients’ organ function were provided. If necessary, patients were administered intensive insulin therapy, which comprised 2 to 4 U of insulin three times a day.

Patients in group B were treated with CRRT in addition to routine treatment. The treatment program is described below. Briefly, intravenous puncture was performed at the center of the patient’s femoral vein, and a central vascular line was created to establish extracorporeal circulation. Filtration was performed using a Swedish Principal Prism CRRT instrument (Gambro, Sweden) with an M100 AN69 membrane filter (International Filter Products, Sun Valley, CA, USA) with continuous venous–venous hemodialysis (CVVHDF) as the filtration mode and the following instrument parameter settings: blood flow control, 3 to 5 mL/(kg·hour); dialysate dosage, 35 to 45 mL/(kg·hour); displacement fluid flow, 35 to 45 mL/(kg·hour), and dialysate: 50 to 120 mL/hour. The displacement solution configuration method was as follows: filter base solution (4000 mL) + 10% KCL (10 mL) + 5% NaHCO3 (250 mL); and osmotic pressure approximately 280 mOsm/L. The treatment was adjusted on the basis of the patient’s response to the treatment.

Data collection

The patients’ indices included main vital signs (body temperature, pulse rate, respiration rate, and blood pressure); urine volume; Acute Physiology Chronic Health Evaluation (APACHE) II score; Sequential Organ Failure Assessment (SOFA) score; white blood cell (WBC) count; and high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor (TNF)-α, albumin, low-density lipoprotein cholesterol, platelet (PLT), hematocrit (HCT), procalcitonin (PCT), bicarbonate (HCO3), serum creatinine, blood potassium (K+), blood sodium (Na+), lactic acid, and urea nitrogen levels. Biochemical indices were detected using a Hitachi 7600 automatic biochemical analyzer (Beijing Biotechnology Co., Ltd., Beijing, China). Hemocyte analysis was performed using the Siemens blood analyzer ADVIA 2120i (Siemens, Munich, Germany). Blood gas analysis was performed using the Sysmex XS-500i automatic blood analyzer (Tokyo, Japan). TNF-α was detected using an enzyme-linked immunosorbent assay (ELISA) reagent kit (PT518, Biyuntian Biotechnology, Shanghai, China). Death information was also collected within 28 days (on the day of death or 28 days after discharge, whichever occurred first).

Outcome measures

Primary outcomes. The primary outcomes were the APACHE II and SOFA scores before and after treatment, which were compared between both groups. The clearance rates of serum creatinine, lactic acid, and urea nitrogen during treatment were calculated as follows: clearance rate = (pre-treatment level – posttreatment level)/pre-treatment level × 100%. Patient mortality was observed up to 28 days after starting treatment. hs-CRP and TNF-α expression levels were determined before and after treatment in both groups.

Secondary outcomes. Clinical data including the patient’s age; body mass index (BMI); sex; medical history; body temperature; heart rate; WBC and PLT counts; albumin, HCT, PCT, HCO3, serum K+, and serum
Na+ levels; and the AKI stage were obtained.

**Statistical methods**

Statistical analysis was performed using the SPSS 20.0 software package (IBM Corp., Armonk, NY, USA). Data were obtained using GraphPad Prism 7 (Shanghai Kabei Enterprise Management Consulting Co., Ltd., Shanghai, China). Count data are presented as the rate (%) using the chi-square test. Measurement data were first subjected to the Kolmogorov–Smirnov test. Data that had a normal distribution are expressed as the mean ± standard deviation (SD). Measurement data between the two groups were analyzed using the t-test and expressed as t. Measurement data that did not have a normal distribution are presented as the median and quartile spacing M(Qu1-Qu3); the rank sum test was used, and the results are presented as a Z-score. The mortality rate of patients within 28 days after starting treatment was analyzed using the Kaplan–Meier analysis and tested using the log-rank test. Statistical significance was set at P < 0.05.

**Results**

**Baseline data**

Among the 60 patients in group A, 35 were men and 25 were women, and among the 55 patients in group B, 31 were men and 24 were women. The mean age of patients in group A was 57.45 ± 10.21 years while that of patients in group B was 60.84 ± 12.37 years. There was no statistical difference between the two groups, including temperature; heart rate; WBC and PLT counts; and albumin, HCT, PCT, HCO3, K+, and Na+ levels (Table 1). All patients received similar treatment except for CRRT in group B.

**Serum creatinine, lactic acid, and urea nitrogen after treatment**

Serum creatinine, lactic acid, and urea nitrogen levels were measured before and after treatment in the two groups, and the clearance rate of these toxins was calculated. After treatment, clearance of serum creatinine, lactic acid, and urea nitrogen were all significantly higher in group B compared with group A (P < 0.001; Table 2 and Figure 1).

**hs-CRP and TNF-α expression decreased after treatment**

After treatment, hs-CRP and TNF-α levels were significantly lower in group B than in group A (P < 0.001, Table 3). Within groups, the decrease in hs-CRP and TNF-α levels after treatment compared with before treatment was significantly greater in group B compared with group A (P < 0.001, Table 4).

**APACHE II and SOFA scores decreased after treatment**

The APACHE II and SOFA scores within each group were significantly lower after treatment compared with before treatment (P < 0.05). Additionally, APACHE II and SOFA scores in group B patients after treatment were significantly lower than those of group A patients after treatment (P < 0.001, Table 5).

**Twenty-eight-day mortality rate was decreased after treatment**

A statistical analysis of the patient mortality between the two groups within 28 days of treatment was conducted and plotted using the Kaplan–Meier survival curve. The log-rank test showed that 28-day mortality in group A was higher (33 patients died at 28 days; mortality rate, 55.0%) than that in group B (11 patients died at
Table 1. Analysis of patient demographic data.

| Factor                  | Group A (n = 60) | Group B (n = 55) | t/χ²/Z | P-value |
|-------------------------|------------------|------------------|--------|---------|
| Age (years)             | 57.45 ± 10.21    | 60.84 ± 12.37    | 1.608  | 0.111   |
| BMI (kg/m²)             | 24.58 ± 1.89     | 24.98 ± 2.05     | 1.089  | 0.279   |
| Sex (n, %)              |                  |                  | 0.046  | 0.831   |
| Male                    | 35 (58.33)       | 31 (56.36)       |        |         |
| Female                  | 25 (41.67)       | 24 (43.64)       |        |         |
| Anamnesis (n, %)        |                  |                  |        |         |
| Diabetes mellitus       | 31 (51.67)       | 32 (58.18)       | 0.492  | 0.483   |
| Hypertension            | 21 (35.00)       | 16 (29.09)       | 0.459  | 0.498   |
| Temperature (°C)        | 36.95 ± 1.08     | 37.01 ± 1.12     | 0.292  | 0.771   |
| Heart rate (beats/minute) | 115.62 ± 21.84  | 109.54 ± 23.15  | 1.449  | 0.150   |
| Albumin (g/L)           | 29.54 ± 5.98     | 28.62 ± 6.99     | 0.760  | 0.449   |
| WBC (×10⁹/L)            | 15.22 ± 10.96    | 12.84 ± 8.21     | 1.309  | 0.193   |
| PLT (×10⁹/L)            | 111.85 ± 52.24   | 102.32 ± 62.58   | 0.889  | 0.376   |
| HCT (%)                 | 30.84 ± 7.25     | 30.31 ± 8.21     | 0.368  | 0.714   |
| PCT (µg/L)              | 10.84 (1.50–79.54) | 11.25 (1.09–84.11) | −1.011 | 0.312   |
| HCO₃⁻ (mmol/L)          | 15.84 ± 5.68     | 16.72 ± 5.99     | 0.809  | 0.420   |
| K⁺ (mmol/L)             | 4.58 ± 1.85      | 4.15 ± 1.44      | 1.382  | 0.170   |
| NA⁺ (mmol/L)            | 138.94 ± 8.54    | 138.41 ± 7.25    | 0.357  | 0.723   |
| Creatinine (µmol/L)     | 132 ± 6.12       | 138 ± 5.32       | 0.561  | 0.410   |
| Urea (mmol/L)           | 13.2 ± 1.23      | 14.1 ± 2.33      | 0.345  | 0.643   |
| Acute renal injury stage|                  |                  |        |         |
| I                       | 32 (53.33)       | 26 (47.27)       | 0.422  | 0.516   |
| II                      | 28 (54.67)       | 29 (52.73)       |        |         |

BMI, body mass index; WBC, white blood cell count; PLT, platelets; HCT, hematocrit; PCT, procalcitonin; HCO₃⁻, bicarbonate; K⁺, serum potassium value; NA⁺, serum sodium value.

Table 2. Serum creatinine, lactic acid, and urea nitrogen clearance rate.

| Group              | Serum creatinine (µmol/L) | Lactic acid (µmol/L) | Urea nitrogen (µmol/L) |
|--------------------|----------------------------|----------------------|------------------------|
| Group A (n = 60)   | 21.84 ± 3.84               | 51.99 ± 8.47         | 31.88 ± 4.15           |
| Group B (n = 55)   | 29.54 ± 4.84               | 67.25 ± 11.25        | 45.28 ± 5.31           |
| t value            | 9.489                      | 8.260                | 15.144                 |
| P value            | <0.001                     | <0.001               | <0.001                 |

28 days; mortality rate, 20%) (P=0.001, Table 6 and Figure 2).

**Discussion**

Sepsis is often accompanied by other diseases in patients with severe sepsis, and the kidney is the most common target organ. Other studies have shown that in over 40% to 75% of patients with acute renal injury, the injury is caused by sepsis, and the mortality rate in these patients is high and continues to increase.

The current clinical treatment for AKI is infusion of intravenous fluids to maintain stable hemodynamics and a stable internal environment and to provide adequate nutritional support. However, rehydration in...
patients without fluid loss or excess rehydration can lead to renal interstitial edema, which further aggravates the deterioration of renal function. Therefore, an effective method to solve this problem is required. This study analyzed the effects of CRRT combined with conventional treatment in patients with sepsis that is accompanied by AKI. The clinical application of CRRT has an obvious promoting effect on waste metabolism, such as urea nitrogen and creatinine. It can also eliminate inflammatory mediators and toxins such as interleukin 1β and TNF-α from the body so that the patient’s internal environment and electrolyte levels can reach a stable state, and the patient’s endothelial blood cells and organs are thereby protected. In this study, the demographic data at baseline showed no statistical difference between the two groups, suggesting that the data were comparable. The clearance rates of serum creatinine, lactic acid, and urea nitrogen were significantly lower in group A than in group B. Mira et al. showed that serum creatinine, lactic acid, and urea nitrogen levels were significantly reduced after compared with before CRRT. In our study, serum creatinine, lactic acid, and urea nitrogen clearance improved after compared with before treatment. In addition, we analyzed hs-CRP and TNF-α expression in

![Figure 1. Comparison of serum creatinine, lactate, and urea nitrogen clearance rates between the two patient groups during treatment.](image)

The clearance rate of serum creatinine, lactic acid, and urea nitrogen group A was significantly lower than that of group B during hospitalization (**P < 0.001**).

### Table 3. hs-CRP and TNF-α expression during treatment in the two patient groups.

| Group       | hs-CRP (mg/L) | Pretherapy | Post-treatment | TNF-α (ng/L) | Pretherapy | Post-treatment |
|-------------|---------------|------------|----------------|--------------|------------|----------------|
| Group A (n = 60) | 58.24 ± 8.66 | 18.65 ± 4.21 | 45.84 ± 10.84 | 30.88 ± 7.58 |
| Group B (n = 55) | 57.25 ± 7.89 | 10.38 ± 2.05 | 44.24 ± 11.36 | 22.58 ± 5.15 |
| t value     | 0.639         | 13.21      | 0.773          | 6.806        |
| P value     | <0.001        | <0.001     | <0.001         | <0.001       |

hs-CRP, hypersensitive C-reactive protein; TNF-α, tumor necrosis factor-α.

### Table 4. The difference in hs-CRP and TNF-α levels before and after treatment in the two groups before and after treatment.

| Index            | Group A (n = 60) | Group B (n = 55) | t value | P value |
|------------------|------------------|------------------|---------|---------|
| hs-CRP (mg/L)    | 38.88 ± 11.27    | 49.67 ± 7.81     | 5.916   | <0.001  |
| TNF-α (ng/L)     | 13.83 ± 5.28     | 20.34 ± 8.14     | 5.130   | <0.001  |

hs-CRP, hypersensitive C-reactive protein; TNF-α, tumor necrosis factor-α.
When microbial invasion or tissue damage occurs in a patient, hepatocytes secrete a large amount of hs-CRP, which significantly increases within a few hours of inflammation and gradually decreases as the disease progresses. TNF-α is mainly produced by the secretion of mononuclear macrophages. As an important inflammatory factor for collective growth and development as well as maintenance of internal environment stability, TNF-α expression increases rapidly when inflammation occurs, and it plays a role in mediating infection, trauma, and immune response. We analyzed the hs-CRP and TNF-α levels in both groups before and after treatment. A significant decrease in the two indicators after treatment was found between the two groups, which suggests that both regimens improved the patient’s condition. However, further analysis showed that hs-CRP and TNF-α expression was significantly lower in group B compared with group A after treatment. This demonstrated that combined treatment with CRRT can effectively reduce the expression of inflammatory factors in patients and improve their condition.

**Table 5.** APACHE II and SOFA scores before and after treatment.

| Group             | APACHE-II Pretherapy | APACHE-II Post-treatment | SOFA Pretherapy | SOFA Post-treatment |
|-------------------|-----------------------|--------------------------|-----------------|---------------------|
| Group A (n = 60)  | 19.49 ± 3.84          | 16.01 ± 2.44*            | 16.25 ± 1.79    | 12.94 ± 1.84*       |
| Group B (n = 55)  | 19.15 ± 4.11          | 13.84 ± 2.12*            | 16.29 ± 1.85    | 7.98 ± 1.62*        |
| t                 | 0.445                 | 5.070                    | 0.118           | 15.285              |
| P                 | 0.657                 | < 0.001                  | 0.906           | < 0.001             |

*There was a difference between before and after treatment within each group (P < 0.05).

APACHE II, Acute Physiology, Chronic Health Evaluation II scoring system; SOFA, Sequential Organ Failure Assessment score.

**Table 6.** Deaths within 28 days in both groups.

| Group             | Day 7 | Day 14 | Day 21 | Day 28 | χ²    | P-value |
|-------------------|-------|--------|--------|--------|-------|---------|
| Group A (n = 60)  | 4 (95.00) | 17 (70.00) | 25 (51.67) | 33 (45.00) | 17.738 | 0.001   |
| Group B (n = 55)  | 1 (96.36) | 4 (90.91)  | 7 (85.45) | 11 (80.00) |       |         |

Data are presented as n (%).

Figure 2. Comparison of mortality between the two groups. Thirty-three patients in group A died within 28 days, which is a mortality rate of 55.00%. Eleven patients in group B died within 28 days, which is a mortality rate of 20.00%. The difference in mortality between the two groups was statistically significant (P = 0.001).
Physiological state and chronic health status of patients. Studies have shown that the higher the APACHE II score, the worse the patient's condition and the higher the mortality rate. SOFA scores are also known as infection-related organ failure scores. The initial application is to evaluate the patients' infection status, which mainly includes respiratory function, liver and kidney function, and cardiovascular function. Keegan et al. showed that the higher the patient's SOFA score, the higher the chance of organ dysfunction and the higher the mortality rate. We calculated the changes in the APACHE II and SOFA scores of patients in both groups before and after treatment and found that there was a significant decrease in the scores in both groups after treatment, and the scores were also significantly lower in group B compared with group A. This suggests that combined treatment with CRRT can effectively improve organ failure and reduce the mortality rate of patients. Moreover, after analyzing patients mortality at 28 days, the mortality rate in group B was also significantly lower than that in group A.

Thus, CRRT can effectively improve the condition of patients with sepsis and AKI, promote the elimination of toxins from the body, and reduce the short-term mortality rate.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by Hainan Natural Science Fund Project (818MS150).

ORCID iD
Xiaozhi Wang https://orcid.org/0000-0002-5527-0628

References
1. Kawanishi H and Takahashi S. [Technical evaluation of medical practice–conversion from things to skill and art. Topics: VI. Issues on fee for medical services in 20 internal medicine fields: 8. Nephrology and Blood Purification committee]. Nihon Naika Gakkai Zasshi. 2014; 103: 3036–3038.
2. Balk RA. Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock. Crit Care Clin. 2000; 16: 337–352, vii.
3. Fleischmann C, Scherag A, Adhikari NK, et al.; International Forum of Acute Care Trialists. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2016; 193: 259–72. doi: 10.1164/rccm.201504-0781OC.
4. Fang Y, Ding X, Zhong Y, et al. Acute kidney injury in a Chinese hospitalized population. Blood Purif. 2010; 30: 120–126.
5. Othus M, Estey E, Gale RP. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016; 375: e9. doi: 10.1056/NEJMc1603847.
6. Talmor D, Greenberg D, Howell MD, et al. The costs and cost-effectiveness of an integrated sepsis treatment protocol. Crit Care Med. 2008; 36: 1168–1174. DOI: 10.1097/CCM.0b013e318168f649.
7. Walkey AJ, Summer R, Ho V, et al. Acute respiratory distress syndrome: epidemiology and management approaches. *Clin Epidemiol*. 2012; 4: 159–169. doi:10.2147/CLEP.S28800.

8. Bloos F, Trips E, Nierhaus A, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. *JAMA Intern Med*. 2016; 76: 1266–1276. DOI:10.1001/jamainternmed.2016.2514.

9. Truche AS, Darmon M, Bailly S, et al. Erratum to: Continuous renal replacement therapy versus intermittent hemodialysis in intensive care patients: impact on mortality and renal recovery. *Intensive Care Med*. 2016; 42: 1523. DOI: 10.1007/s00134-016-4418-0.

10. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. *Intensive Care Med*. 2017; 43: 304–377. doi: 10.1007/s00134-017-4683-6.

11. Romagnoli S, Ricci Z and Ronco C. CRRT for sepsis-induced acute kidney injury. *Curr Opin Crit Care*. 2018; 24: 483–492. DOI: 10.1097/MCC.0000000000000544.

12. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions conference. *Crit Care Med*. 2003; 31: 1250–1256. DOI: 10.1097/01.CCM.0000050454.01978.3B.

13. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med*. 2007; 147: 573–577. DOI: 10.7326/0003-4819-147-8-200710160-00010.

14. Barbar SD, Clerc-Jehl R, Bourredjem A, et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. *N Engl J Med*. 2018; 379: 1431–1442. doi: 10.1056/NEJMoa1803213.

15. Bellomo R, Wan L, Langenberg C, et al. Septic acute kidney injury: new concepts. *Nephron Exp Nephrol*. 2008; 109: e95–e100. DOI: 10.1159/000142933.

16. Shaw AD, Schermer CR, Lobo DN, et al. Impact of intravenous fluid composition on outcomes in patients with systemic inflammatory response syndrome. *Crit Care*. 2015; 19: 334. DOI: 10.1186/s13054-015-1045-z.

17. Rosner MH, Ostermann M, Murugan R, et al. Indications and management of mechanical fluid removal in critical illness. *Br J Anaesth*. 2014; 113: 764–771. DOI: 10.1093/bja/aeu297.

18. Abdollahi A, Shoar S, Nayyeri F, et al. Diagnostic value of simultaneous measurement of procalcitonin, interleukin-6 and hs-CRP in prediction of early-onset neonatal sepsis. *Mediterr J Hematol Infect Dis*. 2012; 4: e2012028. DOI: 10.4084/MJHID.2012.028.

19. Violo L and De Francesco M. Timing of continuous renal replacement therapy. *JAMA Surg*. 2018; 153: 289–290. DOI: 10.1001/jamasurg.2017.5037.

20. Mira JP, Cariou A, Grall F, et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. *JAMA*. 1999; 282: 561–568.

21. Opperman T, Ling LL and Moir DT. Microbial pathogen genomes - new strategies for identifying therapeutic and vaccine targets. *Expert Opin Ther Targets*. 2003; 7: 469–473. DOI: 10.1517/14728227.4.4.469.

22. Keegan MT, Gali B, Findlay JY, et al. APACHE III outcome prediction in patients admitted to the intensive care unit after liver transplantation: a retrospective cohort study. *BMC Surg*. 2009; 9: 11. DOI:10.1056/NEJMoa1033213.

23. Wolbers JG, Dallenga AH, van Linge A, et al. Identifying at diagnosis the vestibular schwannomas at low risk of growth in a long-term retrospective cohort. *Clin Otolaryngol*. 2016; 41: 788–792. DOI: 10.1111/coa.12661.

24. Raith EP, Udy AA, Bailey M, et al. Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for inhospital mortality among adults with suspected infection admitted to the intensive care unit. *JAMA*. 2017; 317: 290–300. DOI: 10.1001/jama.2016.20328.